Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects

• Status: Completed
• Trial end date: 2017-12-29
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the physician preference) but the idea is to quantify safety, efficacy and side effects for each of these doses.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: St. Luke's-Roosevelt Hospital Center
• Treatments: Anesthetics; Bupivacaine; Fentanyl

Criteria

Inclusion Criteria:

• ASA (American Society of Anesthesiologists Physical status) 1-2 parturients at term requesting labor analgesia

• between 37 and 42 weeks gestational age

• maternal age of 18 years or greater

Exclusion Criteria:

• Parturients with pre-eclampsia

• History of pregnancy induced hypertension

• Patients in whom a spinal anesthetic is contraindicated (e.g. coagulopathy, local infection) or those in whom a CSE cannot be performed

• Patients with non reassuring fetal heart rate tracings prior to placement of the CSE